医学
痤疮
痤疮丙酸杆菌
红霉素
克林霉素
抗菌剂
抗生素耐药性
强力霉素
抗生素
皮肤病科
丙酸杆菌
微生物学
抗药性
金黄色葡萄球菌
四环素
观察研究
分离(微生物学)
微生物群
皮肤感染
作者
Arati Bhadade,Jogender Yadav,Varshith Veeramachaneni,Dinesh Asati,Debasis Biswas,Shashwati Nema
标识
DOI:10.4103/jfmpc.jfmpc_365_25
摘要
A BSTRACT Context: Acne vulgaris, a common skin disorder, primarily affects adolescents and often results in both inflammatory and noninflammatory lesions. Cutibacterium acnes ( C. acnes ) plays a central role in the pathogenesis, and the emergence of antimicrobial resistance (AMR) in C. acnes poses a significant challenge in acne treatment. Aims: This study aims to assess the AMR trends of C. acnes isolates from acne vulgaris patients for commonly used antimicrobial agents. Settings and Design: Setting: Tertiary care teaching hospital in Central India. Design: Observational cross-sectional study. Methods and Material: A total of 109 patients with pustular acne vulgaris were recruited over 15 months. Skin swabs were collected from lesions, cultured on Propionibacterium Isolation agar, and identified by conventional microbiological methods. Antimicrobial susceptibility testing (AST) was conducted using the Epsilometer test (E-test) to assess the AMR trends to clindamycin, erythromycin, doxycycline, and azithromycin. Results: C. acnes was isolated from 29.35% of acne cases. Most of the acne vulgaris cases belonged to 18–25 years of age (77.98%) and were male patients (62.38%). Resistance to two or more classes of antibiotics was observed in 25% of isolates. Maximum resistance was observed for macrolide groups of antimicrobial agents, that is, erythromycin and azithromycin, while doxycycline (93.7%) and clindamycin (81.2%) exhibited good susceptibility. Conclusions: This study highlights a significant concern regarding AMR in C. acnes , particularly to macrolides. Judicious use of antibiotics and adopting non-antibiotic treatments, such as retinoids and benzoyl peroxide, are crucial to mitigate the growing resistance issue and improve acne management.
科研通智能强力驱动
Strongly Powered by AbleSci AI